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Abstract
Calcification is a detrimental process in vascular ageing and in diseases such as atherosclerosis and arthritis. In particular,
small calcium phosphate (CaP) crystal deposits are associated with inflammation and atherosclerotic plaque de-stabilisation.
We previously reported that CaP particles caused human vascular smooth muscle cell (VSMC) death and that serum reduced
the toxic effects of the particles. Here, we found that the serum proteins fetuin-A and albumin ($1 mM) reduced intracellular
Ca2+ elevations and cell death in VSMCs in response to CaP particles. In addition, CaP particles functionalised with fetuin-A,
but not albumin, were less toxic than naked CaP particles. Electron microscopic studies revealed that CaP particles were
internalised in different ways; via macropinocytosis, membrane invagination or plasma membrane damage, which occurred
within 10 minutes of exposure to particles. However, cell death did not occur until approximately 30 minutes, suggesting
that plasma membrane repair and survival mechanisms were activated. In the presence of fetuin-A, CaP particle-induced
damage was inhibited and CaP/plasma membrane interactions and particle uptake were delayed. Fetuin-A also reduced
dissolution of CaP particles under acidic conditions, which may contribute to its cytoprotective effects after CaP particle
exposure to VSMCs. These studies are particularly relevant to the calcification observed in blood vessels in patients with
kidney disease, where circulating levels of fetuin-A and albumin are low, and in pathological situations where CaP crystal
formation outweighs calcification-inhibitory mechanisms.
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Introduction
The biosynthesis of calcium phosphate (CaP) crystals is a tightly
regulated physiological process occurring in bones and teeth.
However, deposition of CaP crystals at non-skeletal locations
(ectopic calcification) occurs in blood vessels in association with
ageing and also in several diseases including atherosclerosis,
arthritis and cancer. The amount of calcification in arteries
correlates positively with the degree of atherosclerosis, and the
presence of calcification in the intima or in the medial layer of
blood vessels is detrimental [1]. Excessive calcification of the
intima and/or media is a very common feature in diabetes and
chronic kidney disease and predicts an increased risk for
cardiovascular events and mortality. Calcification has been
regarded as a silent marker of disease, but CaP crystals are known
to be damaging in inflamed joints, and there is emerging evidence
supporting a pro-inflammatory, destabilising effect of small CaP
crystals in atherosclerosis [2–5]. Indeed, small CaP crystals
(generally less than 5 mm) and other forms of particles have been
shown to stimulate various cell signalling pathways resulting in
profound effects on cell function, including proliferation, matrix
degradation, cytokine secretion and cell death [6,7]. CaP particles
in arteries are found within or near vascular smooth muscle cells
(VSMCs) and inflammatory cells. The micro- and nanocrystalline
deposits are particularly associated with areas of atherosclerotic
plaque stress and rupture, possibly because of engulfment by
phagocytic cells causing inflammation and also via macrophage
and VSMC death.
We have previously reported that CaP particles, either extracted
from human calcified blood vessels or synthetic nanoparticles,
induced VSMC death in vitro [8]. VSMC death in blood vessels is
expected to have several consequences: to encourage inflammation
via factors produced from apoptotic and necrotic cells; to weaken
the fibrous cap enclosing atherosclerotic plaques due to loss of
matrix-producing VSMCs; and to promote further calcification
via generation of nucleation sites on dead cells. These effects could
contribute to atherosclerotic plaque destabilisation and plaque
rupture, leading to myocardial infarction or stroke.
Our previous studies found that CaP particles isolated from
calcified atherosclerotic tissue were less potent in inducing cell
death compared with synthetic CaP particles [8]. In addition,
serum appeared to reduce the cytotoxic effects of synthetic CaP.
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We hypothesised that the observed reduced potency of the human-
derived particles was due to their association with serum proteins
such as fetuin-A and albumin [9,10]. The fetuin family comprises
two members: fetuin-A (originally termed ‘fetuin’ and also known
as a2-Heremans Schmid glycoprotein) and fetuin-B that are highly
expressed, circulating liver-derived proteins [11]. Both are
members of the cystatin superfamily of protease inhibitors.
Fetuin-A is a potent inhibitor of calcification [12] and fetuin-B
has a critical role in fertilisation [13]. In mice lacking fetuin-A,
extensive calcification occurs in soft tissues indicating that
circulating fetuin-A is required to prevent calcification. In studies
of patients with chronic kidney disease, low levels of circulating
fetuin-A have been associated with increased artery calcification
and higher mortality rates [14,15]. Fetuin-A has a high affinity for
hydroxyapatite crystals and is thought to function by binding small
CaP particles via a domain particularly rich in acidic residues,
stabilising and clearing them to phagocytes for removal [16].
Fetuin-A also has an anti-inflammatory function, dampening the
effects of CaP particles in neutrophil stimulation, and also in
macrophage cytokine release and induction of apoptosis [17,18].
Additionally, fetuin-A has been shown to accumulate in VSMC-
derived matrix vesicles, preventing them from initiating and
propagating calcification [19]. The function of albumin in
calcification is less clear in comparison with fetuin-A, but albumin
has been described as a mineral chaperone, mediating the
clearance of calciprotein particles (CPPs) [20]. We therefore
aimed to determine whether fetuin-A or albumin could affect CaP
particle-induced VSMC death.
Materials and Methods
Ethics Statement
Patients gave written informed consent for tissue samples to be
used for research, on a standard hospital consent form. Ethical
approval for use of human VSMC cultures was approved by the
Cambridgeshire 1 Research Ethics Committee.
Cell Culture
Human arterial VSMCs were grown and maintained in M199
(Sigma) containing 20% foetal bovine serum (PAA), buffered with
3.7 mg/mL NaHCO3 and 5% CO2 and supplemented with
100 IU/mL penicillin, 100 mg/mL streptomycin and 4 mM L-
glutamine (Sigma). VSMCs were isolated from the medial layer of
arterial tissue and were kindly provided by Prof. Martin Bennett
(Addenbrooke’s Hospital, Cambridge). In some experiments,
human VSMCs purchased from Lonza were cultured in SM-
basal medium (Lonza) supplemented with 5% foetal bovine serum,
insulin, human fibroblast growth factor, human epidermal growth
factor and gentamycin. Cells were used between passages 3 and
15.
Materials and Nanoparticles
Non-functionalised (CaP particles without attached chemicals or
proteins) and protein-functionalised CaP nanoparticles (CaP
particles with fetuin-A or albumin attached) were prepared by
fast pumping of an aqueous solution of calcium lactate (9.0 mM;
Merck) and an aqueous solution of diammonium hydrogen
phosphate (5.4 mM; Merck). The pH of both solutions was
adjusted to 8.0 by NaOH and afterwards sterile filtered through
Filtropur S plus (0.2 mM). The precipitation reaction was achieved
by rapidly pumping (5 mL/min) both solutions into a glass vessel
under sterile conditions. Protein-functionalised CaP nanoparticles
were prepared by simultaneous addition of 2 mL/min of aqueous
protein solutions. The nanoparticles were functionalised with
either fetuin-A from foetal bovine serum (1 mg/mL, suitable for
cell culture, Sigma) or albumin from bovine serum, (1 mg/mL;
suitable for cell culture, Serva). Then the prepared suspensions of
nanoparticles with protein were immediately centrifuged at
900 rpm for 3 min for non-functionalised and albumin-functio-
nalised nanoparticles and at 4000 rpm for 3 min for fetuin-A-
functionalised nanoparticles. The supernatant was removed and
the nanoparticles (CaP+protein) were resuspended in 200 times
less water volume than the initial nanoparticle dispersion (see
Table 1 for explanation of particle abbreviations).
The concentration of Ca2+ in synthesised CaP nanoparticles was
quantified by atomic absorption spectroscopy (AAS; M-Serie,
Thermo Electron). The concentrations of particles used in this
study are stated as mg/mL in terms of Ca2+ content, rather than
weight of the nanoparticles. The content of calcium phosphate
may be estimated by assuming the stoichiometry of hydroxyap-
atite, Ca5(PO4)3OH, and multiplying the calcium content by
M(hydroxyapatite)/(5.M(Ca)) = 502/200= 2.51. The morphology
of freshly prepared nanoparticles was characterised with scanning
electron microscopy (SEM; ESEM Quanta 400 FEG, gold/
palladium sputtering). The particle diameter was between 30
and 60 nm in case of non-functionalised or fetuin-A-functionalised
nanoparticles and between 100 and 200 nm in case of albumin-
functionalised CaP nanoparticles. Each type of the characterised
nanoparticles had a spherical shape after the initial synthesis. Note
that the morphology of prepared CaP nanoparticles was investi-
gated directly after the resuspension procedure. All nanoparticle
preparations were stored in sterile water at 4uC and under these
conditions, within 2 days the particles changed shape (or ‘ripened’)
to needle-like shapes. The particles were not colloidally dispersed
and therefore agglomerated. Particle solutions were vortexed
immediately prior to addition to cells. All assays were performed
with particles stored for at least 2 days and particles were checked
for sterility using an endotoxin testing kit (stocks of particles had ,
0.5 EU/ml endotoxin, Pierce). The protein content of functiona-
lised particles was determined by incubating particles in 0.1 M
HCl for 30 minutes and measuring protein concentration using a
BCA protein assay (Pierce). Stock solutions of CaP functionalised
with fetuin-A (CaP/F) contained 88 mg/mL protein and
0.795 mg/mL Ca2+, and CaP functionalised with albumin
(CaP/A) contained 205 mg/mL protein and 1.84 mg/mL Ca2+.
In separate experiments using soluble bovine fetuin-A and
albumin (both cell culture suitable, Sigma) were prepared as stocks
at 200 mM in water, filter sterilised, and stored at 220uC. Fetuin
(Sigma) was confirmed to contain fetuin-A by Western analysis
using an anti-fetuin-A rabbit polyclonal antibody kindly provided
by Prof. W. Jahnen-Dechent, Aachen, Germany (data not shown).
Human plasma-derived fetuin-A was used in some experiments
and prepared as for bovine fetuin-A (Calbiochem).
Toxicity Assay
An assay using propidium iodide (PI) as a measure of cell death
was modified from Dengler WA et al, 1995 [21]. Briefly, cells were
plated in 96-well plates at a density of 5,000 cells per well in
medium containing serum. After an overnight incubation to allow
adherence, cells were treated with or without CaP and/or various
agents in serum-free M199 containing 1 mg/mL PI (1 mg/mL
solution, Life Technologies). After 1 hour, the cells were washed 2
times with physiological buffer (see below) and PI uptake into dead
cells was quantified using a Pherastar plate reader with optic
module (peak excitation 520 nm, emission .610 nm). Autofluo-
rescence was estimated in cells incubated as above but in the
absence of PI. An average of the autofluorescence (blank) levels
was subtracted from all samples for each experiment.
Calcium Phosphate Nanoparticles and Vascular Smooth Muscle
PLOS ONE | www.plosone.org 2 May 2014 | Volume 9 | Issue 5 | e97565
Measurement of Intracellular Ca2+
Measurement of cytosolic Ca2+ was performed by monitoring
fura-2 fluorescence of VSMCs adhered to glass coverslips using an
Olympus Cell‘R imaging system. Human VSMCs were plated on
glass coverslips at a density of 50,000 cells per well in a 12-well
plate in culture medium supplemented with serum. The following
day, the cells were loaded with 1 mM fura-2 acetoxymethyl ester
(Life Technologies, 30 minutes incubation followed by a 30-
minute period for de-esterification) in a freshly prepared physio-
logical buffer containing essential amino acids (NaCl, 121 mM;
KCl, 5.4 mM; MgCl2, 0.8 mM; CaCl2, 1.8 mM; NaHCO3,
6 mM; D-glucose, 5.5 mM; Hepes, 25 mM; essential amino acids
(diluted from a 506stock, PAA), pH 7.3). A single glass coverslip
with adherent cells was mounted on the stage of the Cell‘R epi-
fluorescence microscope in a temperature-controlled chamber
(37uC). Fluorescence images were obtained with alternate excita-
tion at 340 and 380 nm (with a 50 ms acquisition time and
exposure every 3 s), while the emitted light was collected at
510 nm. Changes in fluorescence for individual cells were
processed and analysed in Excel to generate ratio of emissions at
the two excitation wavelengths, which is directly correlated to the
amount of intracellular Ca2+. Calibration of intracellular Ca2+
levels was achieved as described previously [22].
Cell Morphology and Imaging PI Uptake
Differential interference contrast (DIC) live cell imaging was
performed in parallel to intracellular Ca2+ monitoring on the
Cell‘R system to monitor cell morphology. In some experiments
PI (1 mg/mL) was added to the extracellular solution at the start of
the experiment and its uptake was monitored in parallel with fura-
2 and DIC imaging. For detection of PI, cells were excited at
490 nm and the emitted light was collected at .620 nm. In some
experiments, CaP particles were removed from VSMC cultures so
that the morphology of underlying VSMCs could be observed. To
remove CaP particles during VSMC culture, Ca2+ -free physio-
logical buffer containing the complexing agent EGTA (4 mM,
pH 7.3) was added to the cells.
Electron Microscopy
VSMCs were incubated in 6-well plates at a density of 200,000
cells/well in growth medium. After 24 hours, cells were incubated
in physiological buffer with or without CaP particles or fetuin-A, at
37uC. At specific time points, cells were rinsed briefly in 0.9%
NaCl and fixed in 2% glutaraldehyde/2% formaldehyde in
0.05 M sodium cacodylate buffer at pH 8.0 at 4uC. Cells were
removed from culture wells using cell scrapers and centrifuged at
10,000 rpm for 5 minutes. Fixed cells were resuspended in 0.05 M
sodium cacodylate, pH 8.0. Osmium tetroxide buffered to pH 8.0
with sodium cacodylate was added to the cells for 1 hour. They
were rinsed in distilled water, dehydrated in an ascending series of
ethanol solutions and embedded in Quetol 651 epoxy resin.
Sections were cut on a Rechert-Jung Ultracut S microtome,
mounted on 400 mesh copper grids. Thin sections were examined
by bright-field transmission electron microscopy (TEM) in an FEI
Tecnai G2 operated at 120 kV. Images were recorded using an
AMT XR60B camera running Deben software.
Measurement of CaP Particle Dissolution
CaP particles (12.5 mg/mL) were incubated in either Ca2+-free
physiological buffer at pH 7.3 or pH 6.0 in the presence or
absence of fetuin-A. Incubations were carried out for 10 minutes at
room temperature and then centrifuged at 13,000 rpm for 10
minutes. Supernatants were removed and CaP pellets were
resuspended in 0.1 M HCl to dissolve particles. The Ca2+ content
of the samples was measured by the cresolphthalein method, as
described previously [23]. Particle morphology analysis was
carried out after a 10-minute incubation in physiological buffer
as detailed above and then immediately applied to 400 mesh
carbon film grids. Grids were imaged using bright-field TEM as
detailed in the ‘electron microscopy’ section above.
Statistics
For PI assays, 4 replicate samples were used to determine the
mean and S.D. for each treatment. Representative traces are
shown for each experiment, with at least 3 different experiments
using different human VSMC isolates showing similar results.
Student’s t-test was used to test significance between two means.
A Fisher’s Exact test was performed to compare numbers of
viable versus dead cells imaged for one hour, compared with cells
from a separate session/treatment on the Cell‘R imaging system.
Results
Toxicity of CaP Particles is Reduced in the Presence of
Fetuin-A or Albumin
We previously observed that foetal bovine serum reduced
intracellular Ca2+ elevations and VSMC death after exposure to
CaP particles. We hypothesised that CaP particle-binding proteins
in serum, such as fetuin-A, could be responsible for this effect. To
investigate if individual serum proteins could affect CaP toxicity,
we tested the effects of bovine-derived fetuin-A and albumin on
VSMC viability. Using PI influx as a measure of VSMC death,
both fetuin-A and albumin reduced CaP-induced toxicity in
VSMCs in a concentration-dependent manner (Fig. 1A and B).
Fetuin-A and Albumin Inhibit Intracellular Ca2+ Elevations
Induced by CaP Particles
We next addressed whether intracellular Ca2+ levels were
affected by the presence of fetuin-A or albumin. In these studies,
fura-2-loaded VSMCs were imaged by time-lapse video micros-
copy and intracellular Ca2+ and cell death were monitored in
individual cells over one hour. Application of CaP particles evoked
Ca2+ signals in cells, and initial elevations in intracellular Ca2+
appeared 14.661.3 min (mean 6 s.e.m., n=16) after CaP particle
Table 1. Explanation of particle abbreviations.
CaP Non-functionalised or ‘naked’ calcium phosphate particles
CaP+fetuin-A CaP particles in a solution containing fetuin-A
CaP+albumin CaP particles in a solution containing albumin
CaP/F CaP particles functionalised with fetuin-A
CaP/A CaP particles functionalised with albumin
doi:10.1371/journal.pone.0097565.t001
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addition (Fig. 2Ai, representative graph and 2Aii). The magnitude
and patterns of intracellular Ca2+ elevations differed in individual
cells after exposure to particles (Fig. 2Aii). Cells that died exhibited
a common substantial increase in intracellular Ca2+, just prior to
cell death, which occurred at 31.361.76 min (n=17) after CaP
addition. Sometimes this was an abrupt Ca2+ elevation, but
generally it was preceded by Ca2+ oscillations. Only those cells
where intracellular Ca2+ levels increased to a particular threshold
died (peak amplitude 0.9360.03; n = 17). VSMCs that survived
exposure to CaP particles displayed smaller amplitude Ca2+
oscillations (peak amplitude 0.5860.04; n=8), compared with cells
that died under the same conditions (P,0.0001). Calibration of
the fura-2 ratio changes into Ca2+ concentration revealed that the
CaP-induced Ca2+ oscillations had an average amplitude of
505 nM. Whereas, the large Ca2+ surge that immediately
preceded cell death was 1520 nM. These data imply that CaP-
induced elevations are not toxic unless a particular threshold is
reached, causing Ca2+ overload and triggering cell death.
Despite the variation in CaP-induced Ca2+ signals generated by
individual cells, clear differences in Ca2+ signals and time of cell
death were observed in VSMCs exposed to CaP particles in the
presence of fetuin-A or albumin. With fetuin-A at a concentration
of 3 mM, intracellular Ca2+ elevations were either not observed or
infrequent in cells treated with CaP particles and all cells survived
Figure 1. Effect of fetuin-A or albumin on CaP-induced VSMC death. VSMCs in 96-well plates were exposed to either control serum-free
medium (no additions) or CaP particles (CaP, 25 mg/mL) in serum-free medium with or without different concentrations of fetuin-A (A) or albumin (B)
for 1 hour. Both fetuin-A and albumin inhibited CaP-particle-induced VSMC death in a concentration-dependent manner, as measured by PI uptake
(fluorescence intensity with blanks subtracted, n=4, means 6 S.D, *P,0.01, **P,0.0001, ***P,0.00001.).
doi:10.1371/journal.pone.0097565.g001
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(Fig. S1). With 1 mM fetuin-A, the response to CaP particles was
smaller than in the absence of fetuin-A, and intracellular Ca2+
elevations were either absent or delayed (Fig. 2Bi and ii). With
0.1 mM fetuin-A, the magnitude and the timing of Ca2+ elevations
Figure 2. Effects of CaP particles on intracellular Ca2+ in the presence and absence of fetuin-A. Experiments were conducted either in the
absence of fetuin-A (A), with 1 mM fetuin-A (B) or 0.1 mM fetuin-A (C). A-C(i) are representative traces showing intracellular Ca2+ changes in individual
fura-2-loaded VSMCs on addition of 25 mg/mL CaP particles (arrow). A(i) Peak amplitude (PA) is indicated after addition of CaP particles. Note that
fura-2 loss coincided with PI uptake, indicating time of cell death. Intracellular Ca2+ changes seen after cell death did not correspond to genuine Ca2+
signals (also explained in Fig. 3A and B). Incubation with 1 mM fetuin-A (B(i)) but not 0.1 mM fetuin-A (C(i)) silenced intracellular Ca2+ activity and
prevented cell death. A-C(ii) Summary of intracellular Ca2+ activity in all VSMCs used for each condition. Each dot represents the area under the curve
calculated for each 2.5 minute interval post CaP particle addition from individual cells. ‘B’ on the x-axis of these graphs represents the baseline, or 2.5
minutes prior to addition of CaP particles. These graphs display the range and magnitude of intracellular Ca2+ elevations after CaP particle addition
from several individual experiments and also show that after addition of 1 mM fetuin-A, Ca2+ activity was vastly reduced and delayed (B(ii)).
doi:10.1371/journal.pone.0097565.g002
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observed in response to CaP particles were not significantly
different from treatments with CaP particles alone (Fig. 2Ci and ii).
We conclude that fetuin-A inhibits Ca2+ elevations and protects
against cell death in a concentration-dependent manner. Similar
results were obtained in experiments using albumin (summarised
in Table 2 and Fig. S2). Human fetuin-A (1 mM) also reduced
Ca2+ elevations and blocked cell death induced by CaP particles
over a 1-hour period (Fig. S3).
We next examined whether CaP particles with fetuin-A or
albumin specifically bound to them would affect VSMC viability.
To achieve this, we synthesised CaP particles in the presence of
fetuin-A or albumin, resulting in functionalised CaP particles that
retained fetuin-A or albumin in aqueous solution. When CaP
particles functionalised with fetuin-A (CaP/F) or albumin (CaP/A)
were added to VSMCs, they reduced VSMC viability (Table 2).
However, CaP/F was far less toxic than CaP/A or CaP particles,
indicating that when bound to CaP, fetuin-A retained its
cytoprotective effect, while albumin did not (Table 2 and Fig. S4
and S5). In addition, fetuin-A (1 mM) abolished the low levels of
cell death induced by CaP/F particles (Fig. S6), suggesting that
fetuin-A in solution may provide extra cytoprotective effects. Since
fetuin-A bound to CaP particles inhibited cell death, we focussed
on the mechanism of fetuin-A protection against VSMC death.
Fetuin-A Acts Extracellularly to Protect against CaP-
particle Induced Death
Fetuin-A is known to bind CaP with high affinity and is
therefore likely to alter the surface properties of CaP particles,
thereby interfering with CaP particle exposure to the cell surface.
Since fetuin-A is rapidly taken up by VSMCs and processed in
endocytic vesicles, another possibility is that fetuin-A may act
within the cell to dampen the effects of CaP particles or activate
pro-survival signals. To test this, VSMCs were pre-incubated with
fetuin-A, and the cell supernatant was then replaced with fetuin-A-
free medium. The fetuin-A pre-treatment followed by removal of
fetuin-A gave no protection against CaP particle-induced cell
death, suggesting that fetuin-A uptake by VSMCs was not the
mechanism for protection against CaP-induced cell death (Fig. 3A
and B). In contrast, simultaneous addition of fetuin-A and CaP
particles to VSMCs was sufficient to prevent Ca2+ signals and cell
death, supporting the hypothesis that fetuin-A rapidly binds CaP
particles (Fig. 3C). We concluded that fetuin-A was required to be
present in the extracellular solution or bound to CaP particles in
order to protect against CaP particle-induced cell death.
CaP Particles Induce Plasma Membrane Damage and
Large Blebs
To gain insight into the mechanism of cell death, we
simultaneously monitored intracellular Ca2+ levels and the
morphology of cells using high resolution DIC image capture.
This latter technique revealed that agglomerated CaP particles
settled rapidly on VSMCs, and that the cells consequently
retracted and produced plasma membrane blebs that gradually
expanded and protruded from the cell surface (Fig. 4Ai and Video
S1). This type of large bleb formation is indicative of plasma
membrane damage [24]. Some blebs retained PI for several
minutes before the whole cell became PI positive, indicating that
the damaged membrane was repaired/extruded via bleb release
(Fig. 4Aii). In the presence of fetuin-A ($1 mM), blebbing did not
occur which supports the hypothesis that fetuin-A protected
against CaP-induced cell damage (Fig. 4Bi and ii).
Fetuin-A Delays CaP Particle Plasma Membrane
Interactions and Damage
Transmission electron microscopy (TEM) analysis revealed that
CaP particles interact with the VSMC plasma membrane and are
taken up into VSMCs as early as 5 minutes after addition of
particles (Fig. 5). Macropinocytosis of clusters of particles was
observed as well as uptake via plasma membrane invagination or
Figure 3. Timing of fetuin-A addition affects the response to
CaP particles. Pre-incubating with fetuin-A (1 mM) for 15 minutes
followed by replacing cell supernatant with fetuin-A-free physiological
buffer gave no protection against cell death on CaP exposure (12.5 mg/
mL) (A and B). The ratio of 340/380 fura-2 values is plotted in A and raw
data is presented in B, showing that when 340 and 380 nm values both
suddenly decline together (fura-2 leak from VSMC), this coincides with
PI influx. The Ca2+ activity observed up to the time of fura-2 loss/PI
influx represents genuine Ca2+ signals, whereas activity seen after this
time point (in A) is not genuine. (C) Simultaneous addition of CaP
(12.5 mg/mL) and fetuin-A (1 mM) had very little effect on VSMC
intracellular Ca2+ and cells survived over one hour of analysis.
Representative traces are shown.
doi:10.1371/journal.pone.0097565.g003
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incorporation of individual particles into cells (Fig. 5A and B).
Focal plasma membrane damage was also commonly observed
after 5 or 10 minutes of particle exposure. Damage at the plasma
membrane was often associated with clusters of particles and
cellular protrusions (Fig 5C), but clusters of particles were also
observed in areas of the cell that appeared to be eroded or
retracting away from the subjacent particles (Fig. 5D). In addition,
individual particles were often seen either bound to the plasma
membrane surface or entering the cell with no apparent damage
after 10 minutes of particle exposure (Fig. 5C). Thus, at early time
points, CaP particles appeared to interact with VSMCs in various
ways. Profound plasma membrane damage was seen in association
with clusters of CaP particles after 30 and 60 minutes of addition
of particles (Fig. 5E and F). Within cells, individual particles were
detected as well as clusters of particles within large cellular
compartments or ‘vesicles’ (Fig. 5F and Fig. 6Ci). From these
observations we postulate that CaP particles can both bind to the
VSMC plasma membrane surface and enter VSMCs via different
Table 2. Cytotoxic effects of CaP particles in the presence or absence of fetuin-A or albumin or functionalised CaP particles (CaP
with fetuin-A attached, CaP/F or with albumin attached, CaP/A) on fura-2 loaded VSMCs.
Dead cells/total cells % death n
Control (no CaP) 0/80 0 15
CaP 82/102 80 17
CaP+fetuin-A (1 mM) 1/27 4 4
CaP+fetuin-A (0.1 mM) 19/22 86 4
CaP+albumin (1 mM) 1/21 5 4
CaP+albumin (0.1 mM) 18/23 78 4
CaP/F 9/49 18 8
CaP/A 14/16 88 3
Stock concentrations of particles contained 2.9 mg/mL Ca2+ for CaP, 0.8 mg/mL Ca2+ for CaP/F and 1.84 mg/mL Ca2+ for CaP/A. The particle concentration used in each
experiment was 25 mg/mL in terms of Ca2+ content. Samples were prepared as a 250 mg/mL solution in 100 ml physiological buffer and added to VSMCs in a chamber
containing 900 ml physiological buffer. All particle solutions were vortexed immediately prior to addition to cells. Raw data are presented, i.e. 82/102 denotes that 82 out
of 102 cells that were imaged died within 1 hour of an experiment. Cell death was determined by fura-2 leak from cells. ‘n’ represents the number of separate
experiments. Representative Ca2+ traces are shown in figure 2 and figures S2, S4 and S5.
doi:10.1371/journal.pone.0097565.t002
Figure 4. CaP particles induce bleb formation in human VSMCs. DIC images of VSMCs in physiological buffer after 1 hour of treatment with
CaP particles (25 mg/mL). CaP particles induced large bleb formation (Ai and ii) and these blebs contained PI (Aii). In the presence of fetuin-A (1 mM)
and CaP particles (25 mg/mL), no blebs were seen (Bi and ii). After 1 hour of CaP and fetuin-A treatment, cells and particles in image Bi were treated
with EGTA (4 mM) in Ca2+ -free physiological buffer to remove particles. After removal of particles, the morphology of underlying cells could be
clearly observed (Bii). Scale bar: 50 mm.
doi:10.1371/journal.pone.0097565.g004
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mechanisms. Our TEM analysis indicates that focal damage to
VSMCs occurs within 5–10 minutes of exposure to CaP particles.
However, the imaging studies described above indicated that loss
of membrane integrity and cell death occurred much later
(approximately 30 minutes, Fig. 3A and B). We postulate that
the early membrane damage is localised at the site of CaP
particle/plasma membrane interaction and does not disrupt
cellular homeostasis. The focal interaction of CaP particles with
membranes may activate repair mechanisms by promoting a
limited influx of Ca2+. This CaP-induced Ca2+ entry may be a
component of the Ca2+ oscillations triggered by CaP addition
(Fig. 2). However, with continued exposure to CaP particles, repair
and intracellular Ca2+ homeostatic mechanisms become over-
whelmed because of Ca2+ overload, and large plasma membrane
blebs are formed as a final attempt to rescue cell integrity.
To investigate whether fetuin-A could affect CaP particle
interaction with VSMCs we used TEM analysis at different time
points after CaP particle exposure (Fig. 6). After 5 minutes, fewer
CaP particle-plasma membrane interactions were observed in the
presence of fetuin-A (1 mM) (Fig. 6Bi and Bii). Similarly,
functionalised CaP/F particles displayed a delay in interaction
with VSMCs compared with non-functionalised CaP particles at
this early time point (Fig. 6Bi and Biii). After 10 minutes of
exposure to CaP/F or CaP+fetuin-A, a greater number of cells
displayed CaP-plasma membrane interactions and uptake of CaP
particles (Fig. 6C), but the percentage of cells displaying these
interactions was still lower compared with CaP particles alone
(Fig. 7A and B). The delay in interaction of CaP particles with
VSMCs in the presence of fetuin-A was likely to contribute to its
cytoprotective effects. However, after 60 minutes of exposure of
VSMCs to CaP particles, there was no distinct difference in TEM
features between cells treated with CaP alone, CaP/F or CaP+
fetuin-A (Fig. 7A and B). These data indicate that fetuin-A delays
the membrane-damaging effects of CaP on VSMCs, but does not
persistently inhibit CaP-VSMC interactions. Thus, the majority of
VSMCs exposed to CaP particles in the presence of fetuin-A
contained intracellular particles after 60 minutes.
Effects of Fetuin-A on CaP Particle Dissolution
The results described above present an interesting paradox. Our
imaging studies and cell death assays suggested that fetuin-A
protected cells against CaP crystals for .60 minutes. In particular,
with CaP+fetuin-A, we did not observe the high amplitude Ca2+
signals that are indicative of disasterous homeostatic loss. TEM
analysis, however, indicated that the degree of CaP-VSMC
interaction and CaP engulfment was the same at 60 minutes. A
plausible explanation for these apparently contradictory observa-
tions is that in addition to delaying CaP-membrane interaction,
fetuin-A reduces the toxicity of CaP particles when they are inside
VSMCs.
To investigate why intracellular CaP particles are less toxic
when fetuin-A is present, we tested whether fetuin-A could affect
CaP particle dissolution. We attempted to mimic intra-endoso-
mal/lysosomal acidic conditions and to examine the effects of
fetuin-A on particle dissolution at neutral or acidic pH. Using a
calcium assay to estimate dissolved Ca2+ from CaP particles, we
found that CaP particle dissolution occurred in physiological
buffer at pH 6.0 (Fig. 8A). However, in the presence of fetuin-A
(1 mM), CaP particle dissolution was inhibited. TEM analysis of
CaP particles exposed to physiological buffer at pH 6.0 revealed
that particles had an altered morphology, appeared partially
fragmented and were smaller than CaP particles in physiological
buffer at pH 7.3 (Fig. 8Bi and Ci). However, fetuin-A treated CaP
particles in physiological buffer at pH 6.0 retained their elongated,
needle-like morphology, implying that fetuin-A protected from
dissolution (Fig. 8Cii). This is consistent with the hypothesis that
fetuin-A stabilises CaP particles and slows their dissolution within
intracellular acidic vesicles. The reduction in CaP dissolution
would thereby prevent or delay cytotoxic Ca2+ elevations arising
inside the cells.
Discussion
Here, we tested whether the CaP crystal-binding plasma
proteins fetuin-A and albumin could affect the toxicity of CaP
particles. We found that both proteins inhibited elevations in
intracellular Ca2+ and reduced cell death during exposure to CaP
particles in a concentration-dependent manner. Although the
Ca2+ elevations in individual cells displayed different patterns, a
large unrecoverable rise in intracellular Ca2+ occurred in all cells
that died, suggesting that high levels of Ca2+ could not be
tolerated, resulting in necrosis. In cells that survived CaP particle
treatment, their intracellular Ca2+ oscillations had lower ampli-
tudes indicating that all cells reacted to CaP exposure in terms of
intracellular Ca2+ elevations but intrinsic heterogeneity of Ca2+
homeostatic mechanisms may be responsible for the observed
differences in survival. Fetuin-A and albumin reduced both toxic
and non-toxic intracellular Ca2+ responses to CaP particles,
suggesting that these proteins may block or delay interactions of
CaP particles with VSMCs.
Levels of fetuin-A or albumin that are normally found in the
circulation (approximately 10 mM) vastly reduced CaP particle-
induced cell death. At lower concentrations of fetuin-A or albumin
($1 mM) a reduction and delay in Ca2+ signals was observed and
cell death was inhibited, while 0.1 mM fetuin-A or albumin
afforded no protection against CaP particles. This suggests that if
levels of fetuin-A or albumin are reduced, they may no longer
protect against CaP particle-induced intracellular Ca2+ elevations
or cell death. Indeed, although fetuin-A appears to be abundant in
the circulation, levels of fetuin-A in healthy, calcification-free
arteries have been reported to be very low or absent, and other
calcification inhibitors such as matrix Gla protein produced by
VSMCs are thought to actively inhibit CaP crystal formation in
arteries [25,26]. Fetuin-A is synthesised in the liver and via the
circulation it accumulates in bone and in calcified arteries and
therefore appears to be sequestered in areas of physiological and
pathological calcification. Fetuin-A has potent anti-calcifying
activity, but much less is known about albumin-CaP interactions.
It is thought that when calcification occurs, fetuin-A and albumin
bind newly formed crystals and prevent them from developing
further and promote their removal via scavenger receptors on
phagocytic cells [16]. This mechanism of inhibition of calcification
is thought to contribute to the maintenance of calcification-free
tissues and is likely to be less efficient if levels of fetuin-A and
albumin are reduced. Indeed, circulating levels of fetuin-A and
albumin are reduced in CKD patients [12,15,27] and one study
reports that albumin levels decrease with ageing [28]. Thus
reduced levels of circulating fetuin-A and albumin in patients
appear to be associated with excessive vascular calcification.
To test the impact of bound versus free fetuin-A and albumin,
CaP particles were synthesised in the presence of these proteins to
create particles with a protein ‘corona’. Clearly, fetuin-A
functionalised particles (CaP/F) were less toxic than naked
particles, implying that the fetuin-A component of the particles
reduced their toxicity. It was interesting that relatively low levels of
cell death occurred with CaP/F particles and that this toxicity was
abolished by incubation with soluble fetuin-A. This suggests that
fetuin-A may have additional cytoprotective effects. The toxicity of
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albumin-functionalised particles (CaP/A) was comparable to
naked particles. The reason for the lack of protection by albumin
in functionalised form is not clear, but we speculate that albumin is
not as potent as fetuin-A when bound to CaP particles. As fetuin-A
inhibited cell death in particle-bound form, we focussed on how
fetuin-A achieved this and how CaP particles interact with
VSMCs.
Our data suggest that the mechanism of CaP particle-induced
Ca2+ elevations and cell death may involve more than one
pathway. TEM studies confirmed that CaP particles were found
within cells, some of which were located to intracellular vesicles,
which supports our previous studies that lysosomal acidification is
involved in CaP particle-induced Ca2+ elevations and cell death
[8]. We also observed that some particles entered cells as
individual particles with no apparent damage to the plasma
Figure 5. Ultrastructural analysis of CaP particle-exposure to VSMCs. VSMCs were incubated with CaP particles (12.5 mg/mL) for specific
times (as indicated) before fixing and processing for TEM analysis. A. Evidence for macropinocytosis of clusters of CaP particles was often observed
after 5 minutes of particle exposure and uptake of individual particles was also seen at this early timepoint (indicated by arrows in A). Clathrin-like pits
were also often observed after CaP particle exposure (B). After 10 minutes of CaP particle exposure, plasma membrane damage was observed in
association with membrane protrusions (C) or ingression (D). Discrete CaP particles were also seen aligning at the plasma membrane surface (arrow in
D). After 30 minutes, areas of plasma membrane damage were observed and these areas contained electron-dense particles (indicated by arrow in E).
B. At 60 minutes, intracellular particle accumulation in clusters or isolated particles (indicated by arrow) were observed and large areas of plasma
membrane rupture (F). Bar = 500 nm.
doi:10.1371/journal.pone.0097565.g005
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membrane and no evident vesicle association. The fate of these
individual particles within VSMCs is not yet known. Furthermore,
we observed plasma membrane damage, typically associated with
clusters of CaP particles. The morphology of the membrane at
sites of damage was particularly interesting, either with cellular
protrusions or clefts displaying interactions with the particles.
These sites show extreme invagination of the plasma membrane
with similarities to those seen at the membrane of striated muscle
at the sites of neuromuscular junctions. Plasma membrane damage
has been described for other types of nanoparticles but to our
knowledge, this is the first description of this type of membrane
protrusion/particle interaction. In human erythrocytes, binding of
monosodium urate or calcium pyrophosphate dihydrate particles
to membranes induces redistribution of transmembrane proteins
leading to ‘pore’ formation [29]. Ca2+ entry via plasma membrane
damage has been shown in other studies to activate repair
Figure 6. TEM images of CaP particle/VSMC interactions in the presence of fetuin-A. TEM images show ultrastructural features observed
after treatment of VSMCs with CaP particles (12.5 mg/mL) 6 fetuin-A (1 mM) or with CaP/F (12.5 mg/mL). Control images from cells exposed to
physiological buffer without CaP particles are shown in Ai and Aii. After 5 minutes of particle exposure (middle panel), CaP/plasma membrane
interactions were observed (Bi) but these interactions were not commonly observed in the presence of fetuin-A (Bii) or with CaP/F particles (Biii). After
10 minutes (lower panel, Ci–iii), CaP particle interactions with the plasma membrane were detected for each condition. Bar = 500 nm.
doi:10.1371/journal.pone.0097565.g006
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mechanisms involving annexins and subsets of lysosomes [30,31].
The finding of isolated PI-rich blebs indicated that PI entered via
damaged membrane sites but that the membrane was rapidly
repaired and the damaged membrane was extruded from the cells.
With continued exposure to CaP particles, constant stimulation of
repair and calcium homeostatic mechanisms is likely to become
dysfunctional, resulting in Ca2+ overload, large bleb formation as a
final attempt to rescue cell integrity and finally cell death.
The cytoprotective effect of fetuin-A may be attributed to
binding CaP particles, thereby delaying plasma membrane
interactions and damage. In addition, fetuin-A protected cells
from the toxic effects of CaP following their entry into cells. With
regard to the latter effect, a plausible mechanism was proposed by
Smith et al [32] where they speculated that fetuin-A could inhibit
lysosomal dissolution of CaP particles within acidic organelles such
as lysosomes, consequently slowing the release of Ca2+ to the
cytosol. In studies in HeLa cells, CaP particles conjugated with the
pH indicator SNARF-1 were shown to be endocytosed and
incorporated into lysosomes, detected by a switch from neutral to
acidic pH on particles [33]. We demonstrated that fetuin-A slowed
the dissolution of CaP particles under acidic conditions which may
explain why VSMCs survived in the presence of fetuin-A, despite
the presence of numerous intracellular CaP particles. TEM
analysis detected clusters of CaP particles in discrete compart-
ments within VSMCs but whether CaP particles bound to fetuin-A
enter endosomes or lysosomes in VSMCs is yet to be determined.
Figure 7. TEM analysis of CaP particle/VSMC interactions in the presence of fetuin-A. A. Images taken at random (see Figure 6) were
assessed for various features including: VSMC plasma membrane interaction; plasma membrane damage; CaP particles seen within cells and CaP
particles seen within discrete intracellular compartments (vesicles) (n $9 for each condition/time point). Controls were samples exposed to serum-
free physiological buffer without particles. A clear trend was observed where the presence of fetuin-A reduced CaP interactions with cells up to 10
minutes of exposure. However, the presence of fetuin-A did not appear to influence CaP interactions/uptake after 60 minutes of exposure. B. As for A,
but the effect of CaP particles on VSMC interactions/uptake was compared with CaP/F (n $9). As for fetuin-A added in solution (A), the presence of
fetuin-A on CaP particles appeared to delay early interactions with VSMC.
doi:10.1371/journal.pone.0097565.g007
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The observed delay in uptake of CaP particles in the presence of
fetuin-A contradicts previous literature suggesting that fetuin-A is
an opsonin, facilitating phagocytosis. Indeed, VSMCs are efficient
phagocytes in terms of apoptotic cell phagocytosis [34]. However,
the mechanism of uptake of CaP particles by VSMCs may not
involve classic receptor-mediated phagocytosis. We demonstrated
evidence for macropinocytosis, plasma membrane invagination
resembling clathrin-mediated endocytosis and also uptake of
individual particles with no evident plasma membrane disruption.
Particle charge is likely to be important in CaP particle uptake.
CaP particles have a net weak positive charge, which could explain
their affinity for the negatively charged phospholipids or
glycosaminoglycans on the plasma membrane surface. Fetuin-A
and albumin are negatively charged at pH 7, and by binding CaP
particles they are expected to change the particle net charge to
negative. Alteration of crystal charge may account for the delayed
cellular uptake and reduced plasma membrane damage of CaP
particles in the presence of fetuin-A. In studies using modified
polystyrene nanoparticles and fluorescently labelled serum, the
entry of these particles into human cell lines was described as a
Figure 8. Fetuin-A inhibits CaP dissolution. CaP particles (12.5 mg/mL) 6 fetuin-A (1 mM) were exposed to Ca2+-free physiological buffer, either
pH 7.3 or pH 6.0 for 10 minutes at room temperature. A. CaP particles were pelleted by centrifugation, resuspended in 0.1M HCl and Ca2+ was
measured using the cresolphthalein method. CaP particles did not dissolve at pH 7.3, but partial dissolution was observed at pH 6.0. Dissolution at
pH 6.0 was inhibited in the presence of fetuin-A (n=3, mean6 S.D.). B. TEM analysis of CaP particles exposed to physiological buffer at pH 7.3 (i) or in
the presence of fetuin-A (ii). C. TEM analysis of CaP particles exposed to physiological buffer at pH 6.0 (i) or in the presence of fetuin-A (ii). Bar = 20nm.
doi:10.1371/journal.pone.0097565.g008
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‘Trojan horse’ effect [35]. The authors suggested that the particle
corona protects membranes from initial damage upon entry into
cells but that when particles accumulate in lysosomes, the corona is
degraded, exposing the bare particle surface. This is thought to
cause lysosomal damage followed by apoptosis, which has also
been observed in studies using cholesterol nanocrystals [7]. These
studies suggest that it is only a matter of time before the protein
corona is removed and the damaging particle surface is exposed
within the cell. In our previous studies where CaP particles were
exposed to VSMCs in the presence of serum, VSMC apoptosis
was stimulated after 24 hours [8]. It would therefore be valuable to
investigate the timing of fetuin-A disassociation from CaP particles
inside cells and to determine the impact on lysosomal integrity and
cell viability.
Other studies have shown that crystalline material may interact
with various circulating proteins, including albumin, fetuin-A,
fibrin, fibronectin, transferrin, acute phase proteins and lipopro-
teins [17,36]. Alterations in shape, size or charge may modulate
particle interactions with cells, including kinetics of phagocytosis
and toxicity, as well as modify crystal-induced inflammation
[18,37]. It is assumed that CaP crystals at all extracellular sites
in vivo will be coated with proteins as CaP has a high affinity to
biomolecules. However, it is possible that bare patches of exposed
crystal may occur. Positron emission tomography (PET) scanning
and 18F-sodium fluoride have been used to detect new bone
formation in patients, a technique that detects F replacement of
OH in newly formed hydroxyapatite. This technique has been
used for several years to study bone formation and in detection of
calcification in tumours. It has recently been developed to detect
active calcification in arteries as a potential marker of unstable
atherosclerotic plaques [38]. Evidence from PET scanning
suggests that at least some of the CaP particles present in vivo
have an exposed surface representing newly formed CaP crystals
or osteoclastic activity on established calcification. From our in vitro
studies, we postulate that CaP particles with an exposed surface
are more toxic to VSMCs than CaP particles bound to proteins
such as fetuin-A and albumin. CaP particles will come in contact
with various proteins but fetuin-A may have stronger binding to
CaP, compared with other proteins. Our studies are therefore
most relevant to situations where fetuin-A levels are low, as
described above, and also where bare CaP particles are exposed
such as pathological situations in which excessive production of
crystals is accompanied by low levels of clearance or areas of
osteoclastic or protease activity in atherosclerotic plaques.
Whether other closely interacting factors such as cholesterol,
glycosaminoglycans or other proteins can influence CaP particle
activity is yet to be determined.
Specific phenotypes of VSMCs may be particularly susceptible
to CaP-induced cell death, since some VSMCs survived CaP
particle treatment. Other cell types such as fibroblasts are
stimulated to proliferate when exposed to similar levels of CaP
particles [39]. In macrophages and chondrocytes, CaP particles
have been shown to induce apoptotic cell death [18,40]. In serum-
free conditions similar to those used in our study, human
monocyte-derived macrophages responded to CaP particles by
inducing formation of a large plasma membrane compartment
that sequesters nanoparticles from the extracellular space without
cellular uptake [41]. The particles are then processed to the cytosol
and degraded gradually, lessening their toxic potential. Dispersion
of agglomerated CaP particles appeared to reduce particle uptake
in human macrophages [42]. From our TEM studies, agglomer-
ates or clusters of particles appeared to be damaging in VSMCs. In
other studies where colloidal dispersions of CaP nanoparticles have
been used, there were no adverse effects on cells [43]. Thus the
toxicity of CaP particles depends on several factors including size,
charge, particle-associated factors, degree of dispersion, target cell
phenotype and time of exposure.
Conclusions
In conclusion, we found that CaP particles induced cell death in
VSMCs, and that this involved progressive plasma membrane
damage and cellular uptake of particles. Plasma membrane
interaction and the observations of variously sized groups of
CaP particles within cells suggest that several different mechanisms
are involved. Both plasma membrane damage and uptake of CaP
particles contribute to intracellular Ca2+ elevations that eventually
overwhelm repair and homeostatic mechanisms causing cell death.
Our results suggest that fetuin-A protects VSMCs from the
cytotoxic effects of CaP by binding to CaP particles, delaying their
interaction with the VSMC plasma membrane, delaying their
accumulation in VSMCs and by stabilising the particles, thereby
slowing their intracellular dissolution. Thus, the binding of fetuin-
A to CaP particles renders them less harmful to VSMCs and is
expected to dampen the pro-inflammatory and pro-calcification
effects of damaged VSMCs. These studies are particularly
relevant to situations where fetuin-A and albumin levels are low
and where new crystal formation outweighs calcification-inhib-
itory mechanisms. Since an extracellular source of fetuin-A is
required to inhibit CaP particle toxicity, this may be beneficial in
therapeutic applications, not only in patients with severe
calcification but also in designing biomaterials with reduced
cytotoxic potential.
Supporting Information
Figure S1 Effects of CaP particles on intracellular Ca2+
in the presence of fetuin-A (3 mM). A and B are represen-
tative traces showing a lack of response to CaP (A) or non-toxic
intracellular Ca2+ changes (B) in individual fura-2-loaded VSMCs
on addition of 25 mg/mL CaP particles (arrow indicates time of
addition) in the presence of 3 mM fetuin-A. Cell death was not
observed in the presence of 3 mM fetuin-A over 1 hour of analysis.
(TIF)
Figure S2 Effects of CaP particles on intracellular Ca2+
in the presence albumin (1 mM). A and B are representative
traces showing intracellular Ca2+ changes in individual fura-2-
loaded VSMCs on addition of 25 mg/mL CaP particles (arrow
indicates time of addition) in the presence albumin (1 mM). Cells
displayed either no intracellular Ca2+ changes (A) or clear
intracellular Ca2+ spikes (B) over 1-hour of analysis. Under these
conditions 1 out of 21 cells died (also detailed in Table 2).
(TIF)
Figure S3 Effects of CaP particles on intracellular Ca2+
in the presence of human fetuin-A (1 mM). A and B are
representative traces showing intracellular Ca2+ changes in
individual fura-2-loaded VSMCs on addition of 25 mg/mL CaP
particles (arrow indicates time of addition) in the presence of
human fetuin-A (1 mM). Cells displayed either no intracellular
Ca2+ changes (A) or clear intracellular Ca2+ spikes (B) over 1 hour
of analysis. Under these conditions no cells died.
(TIF)
Figure S4 Effects of functionalised CaP/F particles on
intracellular Ca2+. A and B are representative traces showing
intracellular Ca2+ changes in individual fura-2-loaded VSMCs on
addition of 25 mg/mL CaP/F particles (arrow indicates time of
addition). All cells displayed intracellular Ca2+ changes in response
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to CaP/F particles over 1 hour of analysis. These intracellular
Ca2+ responses were either non-toxic (40 out of 49 cells, 82% as in
A) or toxic (9 out of 49 cells, as in B, also detailed in Table 2).
(TIF)
Figure S5 Effects of functionalised CaP/A particles on
intracellular Ca2+. A and B are representative traces showing
intracellular Ca2+ changes in individual fura-2-loaded VSMCs on
addition of 25 mg/mL CaP/A particles (arrow indicates time of
addition). All cells displayed intracellular Ca2+ changes in response
to CaP/A particles over 1 hour of analysis. These intracellular
Ca2+ responses were either non-toxic (2 out of 16 cells, 12% as in
A) or toxic (14 out of 16 cells, 88%, as in B, also detailed in
Table 2).
(TIF)
Figure S6 Effects of functionalised CaP/F particles on
intracellular Ca2+ in the presence of fetuin-A (1 mM). A
and B are representative traces showing intracellular Ca2+ changes
in individual fura-2-loaded VSMCs on addition of 25 mg/mL
CaP/F particles (arrow indicates time of addition) in the presence
of fetuin-A (1 mM). No cells died with this treatment over 1 hour of
analysis. Two different types of intracellular Ca2+ responses were
observed, either no response (A), or cells displaying small changes
in intracellular Ca2+ (B).
(TIF)
Video S1 CaP particles induce bleb formation in human
VSMCs. Video showing DIC images of VSMCs in physiological
buffer with live addition of CaP particles (25 mg/mL) over 1 hour
of imaging.
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